Q3 2025 Kura Oncology Inc Earnings Call Transcript
Key Points
- Kura Oncology Inc (KURA) is on track with the FDA review of Ziftomenib for relapsed and refractory NPM1 mutated AML, with a PDUFA target action date of November 30, 2025.
- Clinical data from the KOMET-001 study shows Ziftomenib has a differentiated and favorable benefit-risk profile, potentially making it the menin inhibitor of choice.
- Kura Oncology Inc (KURA) has advanced rapidly into the KOMET-017 Frontline Phase III trials, targeting enrollment at over 150 global sites.
- The company has received $105 million in milestone payments this year, with expectations of approximately $315 million more in near-term milestone payments.
- Kura Oncology Inc (KURA) maintains a strong financial position with cash, cash equivalents, and short-term investments sufficient to fund operations through 2027.
- Research and development expenses increased significantly to $67.9 million in Q3 2025 from $41.7 million in Q3 2024.
- General and administrative expenses also rose to $32.8 million in Q3 2025 compared to $18.2 million in the same period of 2024.
- Net loss for Q3 2025 was $74.1 million, up from a net loss of $54.4 million in Q3 2024.
- Cash, cash equivalents, and short-term investments decreased to $549.7 million as of September 30, 2025, from $727.4 million as of December 31, 2024.
- There is a competitive landscape with existing menin inhibitors, and Kura Oncology Inc (KURA) faces challenges in differentiating Ziftomenib from competitors.
Good day, everybody. My name is Dani, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology third-quarter 2025 conference call. (Operator Instructions) At this time, I would like to turn the call over to Greg Mann from Kura Oncology. Thank you.
Thank you, Dani. Good morning, and welcome to Kura Oncology's third-quarter 2025 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Tom Doyle, Senior Vice President, Finance and Accounting; Dr. Mollie Leoni, Chief Medical Officer; and Brian Powl, Chief Commercial Officer, are also on the call and available to answer questions.
Before I turn the call over to Dr. Wilson, we remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today, and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Kura's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
